Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health reported Q3 2026 revenue of $401.6 million, up 69% year over year, but narrowed its full-year revenue guidance and cut its adjusted EBITDA forecast, sending shares down sharply.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Hims & Hers Health posted a surprise third-quarter earnings loss and narrowed its sales outlook while cutting its profit forecast due to contracting margins. Following these developments, the company's stock tumbled and shares fell as investors weighed the financial results and guidance. The story quieted without a definitive conclusion in the coverage.
Epilogue added 4d ago, after coverage quieted.
The brief
Hims & Hers Health (NYSE: HIMS) announced third-quarter 2026 results after the market closed on November 9, 2026. The company reported revenue of $401.6 million, a 69% increase from the same quarter a year earlier, and total subscribers of 2.2 million, up 54% year over year, according to the company's investor relations release and Reuters. Net loss widened to $14.9 million, or $0.07 per share, compared with a net loss of $3.2 million, or $0.02 per share, in Q3 2025. Adjusted EBITDA was $33.1 million, representing an 8.2% margin, down from $24.5 million and a 10.3% margin a year earlier.
The company narrowed its full-year 2026 revenue guidance to $1.53 billion to $1.55 billion, down from a prior range of $1.54 billion to $1.58 billion, and lowered its adjusted EBITDA outlook to $130 million to $135 million from $140 million to $150 million previously. The Wall Street Journal reported that the midpoint of the new revenue range implies about 55% growth for the year, while the adjusted EBITDA midpoint suggests a margin near 8.7%, below the roughly 9.5% margin implied by the prior guide. Reuters said the company cited higher marketing spend, increased costs from its GLP-1 weight-loss offerings, and continued investment in international expansion and AI tools as reasons for the margin pressure.
Shares fell about 15% in after-hours trading following the release, according to Yahoo Finance and Investor's Business Daily. Quiver Quantitative noted the stock was down 7.3% during the regular session ahead of the report, as investors weighed the recent expansion of access to Eli Lilly's branded obesity medicines Zepbound and Foundayo through the Hims & Hers platform. The company said the agreement allows eligible patients to access those medicines, but analysts have questioned whether the arrangement will compress margins or increase operating costs. Barron's and Benzinga highlighted that the market reaction reflects concern over the path to profitability amid rapid top-line growth. The company's next earnings release has not been dated in the provided materials.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6d ago.
Quick answers
What were Hims & Hers Health's Q3 2026 revenue and subscriber numbers?
Revenue was $401.6 million, up 69% year over year, and total subscribers reached 2.2 million, up 54% year over year.
How did the company change its full-year 2026 guidance?
It narrowed revenue guidance to $1.53 billion-$1.55 billion from $1.54 billion-$1.58 billion and cut adjusted EBITDA guidance to $130 million-$135 million from $140 million-$150 million.
Why did shares fall after the earnings release?
Shares dropped about 15% in after-hours trading as the lowered profit forecast and margin contraction overshadowed strong revenue and subscriber growth.
Coverage (19)
- How Investors Are Reacting To SELLAS Life Sciences Group Stock As Final Trial Analysis Begins Simply Wall St · 3d ago
- Sellas Life Sciences shares jump as key leukemia trial results near TradingView · 3d ago
- SLS SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing GuruFocus · 3d ago
- Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML CancerNetwork · 3d ago
- SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update Sellas Life Sciences · 3d ago
- Hims & Hers posted a surprise Q3 2026 earnings loss and cut its forecast qz.com · 6d ago
- What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call Yahoo Finance · 6d ago
- HIMS Stock Tumbles After-Hours On Surprise Q3 Loss And Cut Profit Outlook: Retail Demands Answers Yahoo Finance · 6d ago
- Hims & Hers Health (HIMS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Yahoo Finance · 6d ago
- Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations Yahoo Finance · 6d ago
- Hims & Hers Health earnings: what to look for from HIMS TradingView · 6d ago
- Hims & Hers Narrows Sales Outlook WSJ · 6d ago
- Hims & Hers cuts 2026 profit forecast as margins contract Reuters · 6d ago
- Hims & Hers Stock Plunges Before Earnings: What to Watch Benzinga · 6d ago
- Hims & Hers Health Shares Fall as Investors Weigh Recent GLP-1 Expansion and Upcoming Earnings Quiver Quantitative · 6d ago
- Hims Takes A Dive On Surprise Losses, Light 2026 Guidance Investor's Business Daily · 6d ago
- Hims & Hers Stock Is Falling Ahead of Earnings. What to Expect. Barron's · 6d ago
- Hers Health, Inc. Reports Third Quarter 2026 Financial Results HIMS investor relations · 6d ago
- The Trade Desk Reports Third Quarter 2026 Financial Results The Trade Desk · 6d ago
Topics
Related trends
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New research outlines five evidence-based strategies to maintain weight loss after discontinuing GLP-1 medications like semaglutide and tirzepatide.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Millions of Americans are altering their GLP-1 drug regimens, skipping doses and stretching supplies due to cost pressures.
Hundreds of children in England prescribed weight-loss jabs, figures show
Recent figures reveal hundreds of children in England are receiving GLP-1 weight-loss prescriptions.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
'Food Network' star Valerie Bertinelli, 66, 'looks 15 years younger' as she wows fans with weight loss update
Valerie Bertinelli, 66, shared an Instagram video showing her weight loss in flared jeans and a sweater, prompting fans to say she looks 15 years younger.